Finafloxacin: first global approval.

Article Details

Citation

Copy to clipboard

McKeage K

Finafloxacin: first global approval.

Drugs. 2015 Apr;75(6):687-93. doi: 10.1007/s40265-015-0384-z.

PubMed ID

25808831 [ View in PubMed

]

Abstract

Finafloxacin is a fluoroquinolone antimicrobial agent that exhibits optimum efficacy in slightly acidic environments. It is being developed by MerLion Pharmaceuticals to treat serious bacterial infections associated with an acidic environment, including urinary tract infections and Helicobacter pylori infections. An otic suspension of finafloxacin (Xtoro), developed by Alcon (a division of Novartis), was recently approved in the USA for the treatment of acute otitis externa, and a Common Technical Document for this indication was also filed in Canada. Oral and/or intravenous formulations are in phase I and II evaluation in uncomplicated urinary tract infections (Germany and Singapore), complicated urinary tract infections and pyelonephritis (Germany and Poland) and H. pylori infection (Germany). This article summarizes the milestones in the development of finafloxacin leading to this first approval for otitis externa.

DrugBank Data that Cites this Article

Drugs

Finafloxacin

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Finafloxacin	DNA gyrase subunit A	Protein	Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)	Yes	Inhibitor	Details
Finafloxacin	DNA topoisomerase 2-alpha	Protein	Humans	Yes	Inhibitor	Details
Finafloxacin	DNA topoisomerase 4 subunit A	Protein	Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)	Yes	Inhibitor	Details